Randomized Controlled Phase 2b Clinical Study in Parallel Groups for the Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma Plus Standard Treatment vs. Standard Treatment Alone of Subjects With Severe COVID-19

Schiffer et al., NCT04712344, IPCO, NCT04712344, Sep 2021
Estimated 58 patient convalescent plasma late treatment RCT with results not reported over 5 years after estimated completion.
29 convalescent plasma RCTs have results missing long after expected1-29
The trials report a total of 3,534 patients, with 15 trials having actual enrollment of 1,143, and the remainder estimated.
Schiffer et al., 1 Sep 2021, Randomized Controlled Trial, Germany, trial NCT04712344 (history) (IPCO). Contact: mario.schiffer@uk-erlangen.de, Holger.Hackstein@uk-erlangen.de.
Late treatment
is less effective